

Special Issue

Henipaviruses

Message from the Guest Editor

Henipaviruses are one of the newest genera within the important Paramyxoviridae family of viruses, which includes measles, mumps, human parainfluenza viruses, Newcastle disease virus, etc. The henipaviruses Nipah (NiV) and Hendra (HeV) viruses are the only known zoonotic paramyxoviruses, and NiV and HeV cause high mortality rates in humans and livestock. Additionally, approximately 20 novel henipaviruses have been discovered in recent years, primarily in bat populations. Thus, henipaviruses offer an excellent model to understand viral zoonosis and spillovers into human populations. This issue aims to review the most important aspects of viral pathogenesis, epidemiology, and attempts for vaccine and therapeutic development against these pathogens.

Guest Editor

Dr. Hector Aguilar-Carreno

Department of Microbiology and Immunology, Cornell University
College of Veterinary Medicine, Veterinary Research Tower T8016A,
Ithaca, NY 14853, USA

Deadline for manuscript submissions

closed (30 June 2021)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/40484

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).